Apollomics to Start China Trial of Multi-Kinase Inhibitor for Solid Tumors

Apollomics, a Foster City , CA - Hangzhou biopharma, was approved to start a Phase I trial of a novel treatment for solid cancers in China . APL-102 is an oral, multi-kinase inhibitor targeting several oncogenic drivers, including  receptor tyrosine kinase, serine/threonine-kinases and platelet-derived growth factor receptors. Apollomics discovered and developed the candidate itself. Last week, Apollomics, which was incubated by OrbiMed, announced it has completed a $124 million Series C financing. More details.... Share this with colleagues: // //